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INTRODUCTION
Heterocyclic compounds, featuring an acridine scaffold, exhibit a wide variety of biological properties and functions and are of interest in organic chemistry. Acridine derivatives (ADs), known since the 19 th century, where first used as pigments and dyes [1] and have been used for commercial purposes for more than a century. Several naturally occurring as well as synthetic ADs are known for antitumor, [2] antioxidant, [3] anticancer, [4] antimicrobial and antiparasitic activities. The acridine nucleus, condensed with additional heterocyclic rings, is also endowed with high cytotoxicity. Specifically, incorporation of five membered heterocyclic rings into the acridine chromophore strongly favors passive cellular drug uptake, rendering the efflux by MDR transporters inefficient. [5] The pyrazole nucleus is of interest for the development of new drugs, because of synthetic accessibility and diverse chemical and biological properties such as fungicidal, antimicrobial, anti-parasitic, anti-inflammatory, anticancer and antiviral activities. [6] Some pyrazoloacridine derivatives are known to fragment DNA through intercalation, causing apoptosis. [7] Within the pyrazoloacridine family, pyrazolo [3,4,5,-kl] acridine (PZA, I) ( Figure. 1) type of compounds containing electron deactivating nitro group proved to be a very exciting new class of antitumor agents, PZA is currently undergoing phase II clinical trials after exhibiting a broad spectrum of antitumor activities in preclinical in-vivo assays. [7, 8] PZA displays solid tumor selectivity, activity against hypoxic cells and cytotoxicity in noncycling cells. [9] In addition, 4,5-dihydropyrazolo [3,4-a] acridines were recently found to function as acetyl cholinesterase inhibitors.
[10]
A well-known method for obtaining quinolines and related poly heterocycles involves the Friedländer quinoline synthesis. Known for more than a century, Friedländer synthesis [11] was applied to prepare quinoline derivatives by condensation of 2-aminoarylketones with carbonyl compounds possessing a reactive methylene group, followed by cyclodehydration [12] . Although considered the most useful method for the preparation of such a class of compounds, the synthetic protocols for polycyclic quinolines reported so far lead to low yields, extended reaction times, and dependence on harmful and often expensive catalyst systems, making the development of a simple, eco-friendly, low cost protocol desirable. We recently reported [13] cyclic imide synthesis using Eaton's reagent [14] (Phosphorus pentoxide-methanesulfonic acid) through cyclisation with Hydrazinylquinolines and cyclic anhydrides and successfully employed the Friedlander method on polycyclic quinolines by using Eaton'sreagent.
Here we wish to report a practical and easy workup method for the synthesis of poly substituted quinolines using Eaton's reagent as alternative to Polyphosphoric acid (PPA) under solvent free conditions.
The reaction of 2-amino-5-nitrobenzophenone (1a) and 1, 3-cyclohexanedione (2a) In demonstrating efficiency and scope of Eaton's reagent for the synthesis of quinolines, cyclic ketones such as 1,3-cyclohexanedione and 5,5-dimethyl-1,3-cyclohexanedione smoothly condensed with 2-aminoaryl ketones to afford the respective polycyclic quinolines (Scheme 2). In most cases, the products were isolated by simple filtration and the crude products were purified by recrystallization from a mixture of ethylacetate and acetonitrile. All compounds (Table. 1) were isolated by recrystallization only and no chromatographic work-up was required to obtain pure products. The structures of 3a, 3c, and 3f were confirmed by single crystal X-ray diffraction ( Figure. 
2, 3, & 4).
Pyrazolo [3,4-a] acridines were synthesized from precursor polycyclic quinolones (3) (Table. 2). The structures of the derivatives 4a and 4b were confirmed by single crystal X-ray diffraction ( Fig.5 & 6 ).
2-(hydroxymethylene)-9-phenyl-3,4-dihydroacridin-1(2H)-one (4) Based on the spectral data, we have assigned the obtained product as 9-Nitro-11-phenyl-4,5-dihydro-2H-pyrazolo [3,4-a] acridine (5a). The identities of all of the compounds (Table. 3) were verified by IR and NMR spectroscopic methods, elemental analysis. The structures of pyrazolo [3,4-a] acridine derivatives 5a and 5b were unambiguously confirmed by single crystal X-ray diffraction ( Fig. 7 & 8) .
CONCLUSION
A simple and efficient method for the synthesis of pyrazolo [3,4-a] acridine derivatives has been reported, which does not required high temperatures or harsh conditions. The significant features of this reaction are the mild reaction conditions, the operational Unless otherwise specified, other reagents were obtained from commercial suppliers.
When known compounds had to be prepared according to literature procedures, pertinent references are given. The purity of the products was tested by TLC with plates coated with silica gel-G using petroleum ether and ethyl acetate in the ratio of 75:25 as developing solvents.
GENERAL PROCEDURE FOR SYNTHESIS OF 9-PHENYL-3,4-

DIHYDROACRIDIN-1(2H)-ONES (3):
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A mixture of an appropriate 2-aminobenzophenone (1, 1 mmol) and 1,3-cyclohexanedione (2a/2b, 1.2 mmol) was heated for 3h in presence of freshly prepared Eaton's reagent (Phosphorus pentoxide-methanesulfonic acid) as a catalyst without any solvent at 90ºC. Then the reaction mass was transferred to an excess saturated sodium carbonate solution (30 mL). The solid obtained was filtered and washed with sufficient water and extracted with EtOAc (2 × 10 mL) and dried over anhydrous magnesium sulphate. Evaporation of the solvent followed by purification on recrystallization from ethyl acetate to yield pure 9-phenyl-3,4-dihydroacridin-1(2H)-one (3). -9-phenyl-3,4-dihydroacridin-1(2H) 
7-Nitro
GENERAL PROCEDURE FOR SYNTHESIS OF (Z)-2-(HYDROXYMETHYLENE)-9-PHENYL-3,4-DIHYDROACRIDIN-1(2H)-ONES (4):
A mixture of an appropriate 9-phenyl-3,4-dihydroacridin-1(2H)-one (3, 1 mmol) and ethylformate(1.2 mmol) was added to freshly prepared sodium methoxide (1g sodium in 10mL methanol) at 0ºC to room temperature for 4-5h. Subsequently the reaction mixture was quenched with ice water (45 mL) and extracted with EtOAc (2 × 10 mL) and dried over anhydrous magnesium sulphate. Evaporation of the solvent afforded yellow solid which was recrystallized from ethyl acetate to give (Z)-2-(hydroxymethylene)-9-phenyl-3,4-dihydroacridin-1(2H)-one (4). 9-phenyl-3,4-dihydroacridin-1(2H) 
GENERAL PROCEDURE FOR SYNTHESIS OF 11-PHENYL-4,5-DIHYDRO-2H-PYRAZOLO[3,4-A]ACRIDINES (5):
A mixture of an appropriate (Z)-2-(hydroxymethylene)-9-phenyl-3,4-dihydroacridin-1(2H)-one (4, 1 mmol) and hydrazine hydrate(1.2 mmol) was refluxed in 20mL ethanol for 2-3 h. Then the reaction mixture was quenched with water and 1:1HCl afforded yellow solid which was recrystallized from ethanol to furnish 11-phenyl-4,5-dihydro-2H-pyrazolo [3,4-a] acridine(5). -11-phenyl-4,5-dihydro-2H-pyrazolo[3,4-a] Figure 3. Room temperature structure of 3c with ellipsoids depicted at the 50% probability level. The material underwent a destructive phase transition upon cooling.
9-Nitro
The structure exhibits disorder in the phenyl ring (C14-C19) and (C8-C13) ring.
Downloaded by [University of Bristol] at 00:28 23 July 2015 Figure 4 . X-ray structure of 3f with ellipsoids depicted ta the 50% probability level.
Only one position of the disordered (C14-C19) Cl2 ring has been shown for clarity.<UL> Figure 5 . X-ray crystal structure of 4c. Thermal ellipsoids depicted at the 50% probability level.
Figure 6. X-ray crystal structure of 4d, thermal ellipsoids depicted at 50% probability level.
Figure 7. X-ray crystal structure of 5c, thermal ellipsoids is depicted at the 50% probability level.
Figure 8. X-ray crystal structure of 5d, thermal ellipsoids depicted at the 50% probability level.
